NMRA News
Archived Headlines
- Brain disease biotech Neumora Therapeutics sets terms for $250 million IPO 09/11/23
- US IPO Week Ahead: Arm set to test the IPO market with biggest listing in nearly two years 09/08/23
- Renaissance Capital's August IPO Market Update 09/01/23
- US IPO Weekly Recap: September IPO roster gets a boost as Arm, Instacart, and other large filers join the pipeline 08/25/23
- US IPO Week Ahead: Quiet August wraps with holdover biotech Adlai Nortye, as big deals prep September IPOs 08/25/23
See more
Top takeaways from the 10 best and worst-performing IPOs of the past two years
New listing activity has been muted in recent years, but sizable issuers have steadily returned to the IPO market, with generally positive results. As is common in the IPO market, some deals have delivered triple-digit gains, while others have fallen well below ...read more
Updated: Renaissance Capital's 3Q 2023 US IPO Market Review
Large Tech IPOs Stage a Comeback in a Volatile 3Q The third quarter of 2023 produced 30 IPOs that raised a combined $7.8 billion, more than the proceeds raised in the full-year 2022 despite no significant increase in deal count from previous quarters. Chip...read more
US IPO Weekly Recap: Arm trades up after raising nearly $5 billion in 2023’s largest IPO to date
Five IPOs raised a combined $5.4 billion this past week, led by the blockbuster IPO of Arm (ARM). Three issuers submitted initial filings. The largest IPO of 2023 so far, Arm priced at the top of the range to raise $4.9 billion at a $52.9 billion market cap. ...read more
Brain disease biotech Neumora Therapeutics prices IPO at $17 midpoint
Neumora Therapeutics, a Phase 3 biotech developing therapies for neuropsychiatric indications, raised $250 million by offering 14.7 million shares at $17, within the range of $16 to $18. The company's pipeline consists of seven clinical and preclinical...read more